Atreca Inc at Cowen Health Care Conference Transcript
Hi, everyone. Welcome again to the second day of TD Cowen's 43rd Annual Health Care Conference. For this next corporate panel, we're very pleased to be discussing novel oncology targets. My name is Tyler Van Buren, senior biotech analyst at TD Cowen. I'm also joined by my colleagues, Boris Peaker, Anvita Gupta, and Eva Privitera.
And then from the companies, we're very pleased to have six companies with us. We have John Orwin, President and CEO of Atreca; Sean McCarthy, CEO and Chairman of CytomX; John Valliant, CEO of Fusion Pharmaceuticals; Norbert Bischofberger, President and CEO of Kronos Bio; David Woodhouse, CEO of NGM Biopharmaceuticals; and Nancy Simonian, President and CEO of Syros Pharmaceuticals.
So the plan is to start with some thematic questions that will be kind of a free for all, open to anyone wants a comment, and then we'll get into some company-specific questions. For those of you in the audience, if you have questions you'd like us to ask, you can go ahead and send them to [solange] @cowen.com. The email is also up on the screen.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |